Trials / Terminated
TerminatedNCT01714817
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 695 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-188667 | |
| DRUG | Mycophenolate mofetil | |
| DRUG | Prednisone | |
| BIOLOGICAL | Placebo matching with BMS-188667 |
Timeline
- Start date
- 2013-01-22
- Primary completion
- 2016-11-21
- Completion
- 2018-05-30
- First posted
- 2012-10-26
- Last updated
- 2021-02-26
- Results posted
- 2017-12-21
Locations
149 sites across 23 countries: United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, Hong Kong, India, Israel, Italy, Japan, Mexico, Peru, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01714817. Inclusion in this directory is not an endorsement.